All In Biotech

Drug Trial Radar · NCT05988203

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

A Randomized, Partially Observer-blind, Dose-escalation, Phase I/II Trial Evaluating the Safety and Immunogenicity of Investigational RNA-based Mpox Vaccine Candidates

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

96

Actual

Start

Sep 21, 2023

Primary completion

Aug 25, 2025

Study completion Mar 4, 2026

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox (mpox). This study was originally planned to include four substudies, i.e., substudy A (SSA), substudy B (SSB), substudy C (SSC), and substudy D (SSD). Sponsor decided not to conduct SSC, thus three substudies (SSA, SSB, and SSD) were conducted. In SSA and SSB, dosing started with an initial sentinel group, followed by the expansion cohort. In SSD, dosing was initiated after the interim analysis of SSA and SSB 1-month post-Dose 2 safety, reactogenicity, and immunogenicity data was received. This study was initially planned to investigate two vaccine candidates (the quadrivalent BNT166a and the trivalent BNT166c). The sponsor decided to not activate the groups with BNT166c.

Conditions

  • Monkeypox

Interventions

  • BNT166aBiological

    Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Solicited Local Reactions At the Injection SiteTime frame: Up to 7 days post any vaccination, and up to 7 days post each vaccination dose (that is, post-dose 1 [up to Day 8]) and post-dose 2 [up to Day 38])
  2. Number of Participants Reporting Solicited Systemic EventsTime frame: Up to 7 days post any vaccination, and up to 7 days post each vaccination dose (that is, post Dose 1 [up to Day 8] and post Dose 2 [up to Day 38])
  3. Number of Participants With At Least One Unsolicited Adverse Event (AE)Time frame: Up to 28 days post any vaccination, and up to 28 days post each vaccination dose (that is, post-dose 1 [up to Day 29] and post-Dose 2 [up to Day 59])
  4. Number of Participants With At Least One Serious Adverse Event (SAE)Time frame: From Dose 1 up to Day 201
  5. Number of Participants With At Least One Adverse Event of Special Interest (AESI)Time frame: From Dose 1 up to Day 201

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • California Research Foundation

    San Diego, California

  • Alliance for Multispecialty Research, LLC

    Kansas City, Missouri

  • Alliance for Multispecialty Research, LLC

    Knoxville, Tennessee

  • University of Washington Virology Research Clinic

    Seattle, Washington

  • Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Royal Surrey County Hospital Foundation Trust, NIHR Royal Surrey Clinical Research Facility

    Guildford, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust of St Thomas' Hospital

    London, United Kingdom

  • Medicine Evaluation Unit Ltd, The Langley Building, Wythenshawe Hospital

    Manchester, United Kingdom

  • University Hospital Southampton

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.